Dynavax Technologies Co. (NASDAQ:DVAX) Shares Acquired by Amundi

Amundi grew its stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 172.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,896 shares of the biopharmaceutical company's stock after purchasing an additional 37,290 shares during the period. Amundi's holdings in Dynavax Technologies were worth $743,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of DVAX. Quest Partners LLC purchased a new stake in Dynavax Technologies in the 3rd quarter worth approximately $237,000. Intech Investment Management LLC purchased a new stake in Dynavax Technologies in the 3rd quarter worth approximately $416,000. Bank of Montreal Can boosted its position in Dynavax Technologies by 8.3% in the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock worth $11,848,000 after purchasing an additional 82,449 shares in the last quarter. PDT Partners LLC purchased a new position in shares of Dynavax Technologies during the 3rd quarter valued at approximately $3,967,000. Finally, Paloma Partners Management Co purchased a new position in shares of Dynavax Technologies during the 3rd quarter valued at approximately $280,000. Hedge funds and other institutional investors own 96.96% of the company's stock.

Dynavax Technologies Price Performance

DVAX stock traded up $0.20 during midday trading on Friday, reaching $13.82. The stock had a trading volume of 3,366,154 shares, compared to its average volume of 1,997,266. The company's fifty day simple moving average is $13.22 and its 200 day simple moving average is $12.40. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.71 billion, a price-to-earnings ratio of 76.78 and a beta of 1.23. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.63.

Remove Ads

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts' consensus estimates of $0.05. The company had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. As a group, sell-side analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on DVAX shares. HC Wainwright reiterated a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group lowered Dynavax Technologies from a "neutral" rating to a "sell" rating and decreased their target price for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Monday, February 24th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.